BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 32991310)

  • 1. Pharmacological agents and natural compounds: available treatments for osteoporosis.
    Martiniakova M; Babikova M; Omelka R
    J Physiol Pharmacol; 2020 Jun; 71(3):. PubMed ID: 32991310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strontium ranelate improves bone microarchitecture in osteoporosis.
    Hamdy NA
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv9-13. PubMed ID: 19783592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One year in review 2018: progress in osteoporosis treatment.
    Figliomeni A; Signorini V; Mazzantini M
    Clin Exp Rheumatol; 2018; 36(6):948-958. PubMed ID: 30526765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New understanding and treatments for osteoporosis.
    Mazziotti G; Bilezikian J; Canalis E; Cocchi D; Giustina A
    Endocrine; 2012 Feb; 41(1):58-69. PubMed ID: 22180055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting WNT signaling in the treatment of osteoporosis.
    Baron R; Gori F
    Curr Opin Pharmacol; 2018 Jun; 40():134-141. PubMed ID: 29753194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab in the treatment of glucocorticoid-induced osteoporosis.
    Coskun Benlidayi I
    Rheumatol Int; 2018 Nov; 38(11):1975-1984. PubMed ID: 30019224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging anabolic treatments in osteoporosis.
    Mosekilde L; Tørring O; Rejnmark L
    Curr Drug Saf; 2011 Apr; 6(2):62-74. PubMed ID: 21524248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].
    Shiraki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis.
    Suzuki A; Sekiguchi S; Asano S; Itoh M
    J Pharmacol Sci; 2008 Apr; 106(4):530-5. PubMed ID: 18431035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Traditional Chinese medicine formulas for the treatment of osteoporosis: Implication for antiosteoporotic drug discovery.
    Zhang ND; Han T; Huang BK; Rahman K; Jiang YP; Xu HT; Qin LP; Xin HL; Zhang QY; Li YM
    J Ethnopharmacol; 2016 Aug; 189():61-80. PubMed ID: 27180315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential anti-catabolic and anabolic properties of strontium ranelate.
    Mentaverri R; Brazier M; Kamel S; Fardellone P
    Curr Mol Pharmacol; 2012 Jun; 5(2):189-94. PubMed ID: 21787286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-resorptives in the management of osteoporosis.
    Miller PD
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):849-68. PubMed ID: 19028360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoanabolic and dual action drugs.
    Tabacco G; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of primary osteoporosis in men.
    Giusti A; Bianchi G
    Clin Interv Aging; 2015; 10():105-15. PubMed ID: 25565793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-osteoporotic drugs and vascular calcification: the bidirectional calcium traffic.
    Yavropoulou MP; Pikilidou M; Yovos JG
    J Vasc Res; 2014; 51(1):37-49. PubMed ID: 24280985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
    Schacht E; Richy F; Reginster JY
    J Musculoskelet Neuronal Interact; 2005; 5(3):273-84. PubMed ID: 16172518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.